<DOC>
	<DOCNO>NCT02050503</DOCNO>
	<brief_summary>An open-label , non-randomized study ass titration , safety efficacy intranasal fentanyl pectin nasal spray treatment secondary breakthrough pain secondary radiation-induced mucositis patient confirm tolerance opioid therapy chronic pain . Study objectives include assessment breakthrough pain episode relate food intake patient mucositis secondary radiotherapy radio-chemotherapy head neck tumor</brief_summary>
	<brief_title>Intranasal Transmucosal Fentanyl Pectin Breakthrough Cancer Pain Radiation-induced Oropharyngeal Mucositis</brief_title>
	<detailed_description>An open , non-randomized study design use assess titration , safety efficacy intranasal fentanyl pectin treatment secondary breakthrough pain patient confirm tolerance opioid therapy chronic pain secondary radiation-induced mucositis . The study plan include 30 evaluable patient multiple center throughout country . The trial comprise screen period , open titration period , open-label treatment period least 12 breakthrough pain episode treat .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Pectin</mesh_term>
	<criteria>A histologically confirm diagnosis head neck carcinoma Treatment form radiotherapy radiochemotherapy Breakthrough pain related swallowing ( one four daily episode ) Treatment control release opioids time inclusion : least 60 mg morphine sulfate daily , least 25 microg transdermal fentanyl per hour , least 30 mg oral oxycodone daily , least 8 mg oral hydromorphone daily Patients without controlled release opioid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Mucositis</keyword>
	<keyword>Breakthrough pain</keyword>
	<keyword>Head Nad neck cancer</keyword>
	<keyword>Intranasal transmucosal fentanyl pectin</keyword>
</DOC>